concentration and liposome concentration independently on murine 
melanoma and Hela cells in vitro , and confirmed by direct 
injection into murine melanoma or other tumors in vivo prior to 
use. Each component, the liposome preparation, and the DNA, will 
be tested for contaminants and toxicity and used only after FDA 
approval, which is currently under review. The liposome solution 
and DNA will be aliquoted in individual sterile vials mixed under 
sterile conditions as described above. 
Escalating doses will be studied in this phase I study. 
Four groups (3 patients each) will be studied sequentially with 
at least 1 month of observation prior to evaluation of the next 
group. Patients in each group will receive intratumor 
injections. Group I will receive 1 injection of < 0.2 ml. Group 
II will receive 3 injections at one session of < 0.2 ml each 
within the same nodule. Group III will receive 5 such injections 
at one session, Group IV will receive 5 injections at one session 
with an increased volume ( <0.4 ml/injection) . 
Doses will be repeated within each subject for whom the 
toxicity treatment is with < grade II. Dose escalation will 
begin if three patients show toxicities < grade III from the 
treatment. If one patient displays toxicity > grade II, the 
treatment will be repeated on three additional patients. If two 
patients develop toxicity > grade II, the dosage will be reduced. 
The maximal tolerated dose will be defined as the dose at which 
two or more patients out of six develop grade III or IV toxicity. 
The treatment dose will be established at one level below the 
maximum tolerated dose. Once the treatment dose is defined, an 
[410] 
Recombinant DNA Research, Volume 15 
